ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Heart Failure Drugs Market Research Report 2026
Published Date: 2026-02-27
|
Report Code: QYRE-Auto-39M8790
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Heart Failure Drugs Market Outlook 2022
BUY CHAPTERS

Global Heart Failure Drugs Market Research Report 2026

Code: QYRE-Auto-39M8790
Report
2026-02-27
Pages:126
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Hikma
TEVA
Cipla Ltd
Merck
Amgen Inc
Roche
Sun Pharma
Mylan NV
Novartis
Pfizer Inc

Heart Failure Drugs Market

The global Heart Failure Drugs market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Heart Failure Drugs competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.
Heart failure occurs when your heart muscle doesn"t pump blood as well as it should.
The market is concentrated as Novartis, Pfizer, AstraZeneca , Hikma, Teva etc. Turkey is the largest consumption place in the Turkey and Middle East & Africa market, with a consumption market share nearly 21%.
This report delivers a comprehensive overview of the global Heart Failure Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Heart Failure Drugs. The Heart Failure Drugs market size, estimates, and forecasts are provided in terms of sales volume (MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Heart Failure Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Heart Failure Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of Heart Failure Drugs Market Report

Report Metric Details
Report Name Heart Failure Drugs Market
Segment by Type
  • ACEI
  • Angiotensin II Receptor Blockers
  • ARNIs
  • Beta Blockers
  • Aldosterone Antagonists
  • Diuretics
by Application
  • Reduced Ejection Fraction
  • Preserved Ejection Fraction
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Novartis, Pfizer, AstraZeneca, Hikma, Teva, Cipla, Merck & Co., Amgen, Roche, Sun Pharma, Mylan
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Provides a detailed analysis of the competitive landscape for Heart Failure Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
  • Chapter 3: Examines Heart Failure Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
  • Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
  • Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
  • Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
  • Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
  • Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

Who are the main players in the Heart Failure Drugs Market report?

Ans: The main players in the Heart Failure Drugs Market are Novartis, Pfizer, AstraZeneca, Hikma, Teva, Cipla, Merck & Co., Amgen, Roche, Sun Pharma, Mylan

What are the Application segmentation covered in the Heart Failure Drugs Market report?

Ans: The Applications covered in the Heart Failure Drugs Market report are Reduced Ejection Fraction, Preserved Ejection Fraction

What are the Type segmentation covered in the Heart Failure Drugs Market report?

Ans: The Types covered in the Heart Failure Drugs Market report are ACEI, Angiotensin II Receptor Blockers, ARNIs, Beta Blockers, Aldosterone Antagonists, Diuretics

1 Heart Failure Drugs Market Overview
1.1 Product Definition
1.2 Heart Failure Drugs by Type
1.2.1 Global Heart Failure Drugs Market Value by Type: 2025 vs 2032
1.2.2 ACEI
1.2.3 Angiotensin II Receptor Blockers
1.2.4 ARNIs
1.2.5 Beta Blockers
1.2.6 Aldosterone Antagonists
1.2.7 Diuretics
1.3 Heart Failure Drugs by Application
1.3.1 Global Heart Failure Drugs Market Value by Application: 2025 vs 2032
1.3.2 Reduced Ejection Fraction
1.3.3 Preserved Ejection Fraction
1.4 Global Heart Failure Drugs Market Size Estimates and Forecasts
1.4.1 Global Heart Failure Drugs Revenue 2021–2032
1.4.2 Global Heart Failure Drugs Sales 2021–2032
1.4.3 Global Heart Failure Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Heart Failure Drugs Market Competition by Manufacturers
2.1 Global Heart Failure Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Heart Failure Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Heart Failure Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Heart Failure Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Heart Failure Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Heart Failure Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Heart Failure Drugs, Date of Entry into the Industry
2.8 Global Heart Failure Drugs Market Competitive Situation and Trends
2.8.1 Global Heart Failure Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Heart Failure Drugs Players Market Share by Revenue
2.8.3 Global Heart Failure Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Heart Failure Drugs Market Scenario by Region
3.1 Global Heart Failure Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Heart Failure Drugs Sales by Region: 2021–2032
3.2.1 Global Heart Failure Drugs Sales by Region: 2021–2026
3.2.2 Global Heart Failure Drugs Sales by Region: 2027–2032
3.3 Global Heart Failure Drugs Revenue by Region: 2021–2032
3.3.1 Global Heart Failure Drugs Revenue by Region: 2021–2026
3.3.2 Global Heart Failure Drugs Revenue by Region: 2027–2032
3.4 North America Heart Failure Drugs Market Facts & Figures by Country
3.4.1 North America Heart Failure Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Heart Failure Drugs Sales by Country (2021–2032)
3.4.3 North America Heart Failure Drugs Revenue by Country (2021–2032)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Heart Failure Drugs Market Facts & Figures by Country
3.5.1 Europe Heart Failure Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Heart Failure Drugs Sales by Country (2021–2032)
3.5.3 Europe Heart Failure Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Heart Failure Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Heart Failure Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Heart Failure Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Heart Failure Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Heart Failure Drugs Market Facts & Figures by Country
3.7.1 Latin America Heart Failure Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Heart Failure Drugs Sales by Country (2021–2032)
3.7.3 Latin America Heart Failure Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Heart Failure Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Heart Failure Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Heart Failure Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Heart Failure Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Heart Failure Drugs Sales by Type (2021–2032)
4.1.1 Global Heart Failure Drugs Sales by Type (2021–2026)
4.1.2 Global Heart Failure Drugs Sales by Type (2027–2032)
4.1.3 Global Heart Failure Drugs Sales Market Share by Type (2021–2032)
4.2 Global Heart Failure Drugs Revenue by Type (2021–2032)
4.2.1 Global Heart Failure Drugs Revenue by Type (2021–2026)
4.2.2 Global Heart Failure Drugs Revenue by Type (2027–2032)
4.2.3 Global Heart Failure Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Heart Failure Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Heart Failure Drugs Sales by Application (2021–2032)
5.1.1 Global Heart Failure Drugs Sales by Application (2021–2026)
5.1.2 Global Heart Failure Drugs Sales by Application (2027–2032)
5.1.3 Global Heart Failure Drugs Sales Market Share by Application (2021–2032)
5.2 Global Heart Failure Drugs Revenue by Application (2021–2032)
5.2.1 Global Heart Failure Drugs Revenue by Application (2021–2026)
5.2.2 Global Heart Failure Drugs Revenue by Application (2027–2032)
5.2.3 Global Heart Failure Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Heart Failure Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Company Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Novartis Heart Failure Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Heart Failure Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 AstraZeneca
6.3.1 AstraZeneca Company Information
6.3.2 AstraZeneca Description and Business Overview
6.3.3 AstraZeneca Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 AstraZeneca Heart Failure Drugs Product Portfolio
6.3.5 AstraZeneca Recent Developments/Updates
6.4 Hikma
6.4.1 Hikma Company Information
6.4.2 Hikma Description and Business Overview
6.4.3 Hikma Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Hikma Heart Failure Drugs Product Portfolio
6.4.5 Hikma Recent Developments/Updates
6.5 Teva
6.5.1 Teva Company Information
6.5.2 Teva Description and Business Overview
6.5.3 Teva Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Teva Heart Failure Drugs Product Portfolio
6.5.5 Teva Recent Developments/Updates
6.6 Cipla
6.6.1 Cipla Company Information
6.6.2 Cipla Description and Business Overview
6.6.3 Cipla Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Cipla Heart Failure Drugs Product Portfolio
6.6.5 Cipla Recent Developments/Updates
6.7 Merck & Co.
6.7.1 Merck & Co. Company Information
6.7.2 Merck & Co. Description and Business Overview
6.7.3 Merck & Co. Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Merck & Co. Heart Failure Drugs Product Portfolio
6.7.5 Merck & Co. Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Company Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Amgen Heart Failure Drugs Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 Roche
6.9.1 Roche Company Information
6.9.2 Roche Description and Business Overview
6.9.3 Roche Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Roche Heart Failure Drugs Product Portfolio
6.9.5 Roche Recent Developments/Updates
6.10 Sun Pharma
6.10.1 Sun Pharma Company Information
6.10.2 Sun Pharma Description and Business Overview
6.10.3 Sun Pharma Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Sun Pharma Heart Failure Drugs Product Portfolio
6.10.5 Sun Pharma Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Company Information
6.11.2 Mylan Description and Business Overview
6.11.3 Mylan Heart Failure Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Mylan Heart Failure Drugs Product Portfolio
6.11.5 Mylan Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Heart Failure Drugs Industry Chain Analysis
7.2 Heart Failure Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Heart Failure Drugs Production Mode & Process Analysis
7.4 Heart Failure Drugs Sales and Marketing
7.4.1 Heart Failure Drugs Sales Channels
7.4.2 Heart Failure Drugs Distributors
7.5 Heart Failure Drugs Customer Analysis
8 Heart Failure Drugs Market Dynamics
8.1 Heart Failure Drugs Industry Trends
8.2 Heart Failure Drugs Market Drivers
8.3 Heart Failure Drugs Market Challenges
8.4 Heart Failure Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Hikma
TEVA
Cipla Ltd
Merck
Amgen Inc
Roche
Sun Pharma
Mylan NV
Novartis
Pfizer Inc
List of Tables
 Table 1. Global Heart Failure Drugs Market Value by Type (US$ Million), 2025 vs 2032
 Table 2. Global Heart Failure Drugs Market Value by Application (US$ Million), 2025 vs 2032
 Table 3. Global Heart Failure Drugs Market Competitive Situation by Manufacturers in 2025
 Table 4. Global Heart Failure Drugs Sales (MT) of Key Manufacturers (2021–2026)
 Table 5. Global Heart Failure Drugs Sales Market Share by Manufacturers (2021–2026)
 Table 6. Global Heart Failure Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
 Table 7. Global Heart Failure Drugs Revenue Share by Manufacturers (2021–2026)
 Table 8. Global Market Heart Failure Drugs Average Price (USD/MT) of Key Manufacturers (2021–2026)
 Table 9. Global Key Players of Heart Failure Drugs, Industry Ranking, 2023 vs 2024 vs 2025
 Table 10. Global Key Manufacturers of Heart Failure Drugs, Manufacturing Sites and Headquarters
 Table 11. Global Key Manufacturers of Heart Failure Drugs, Product Types and Applications
 Table 12. Global Key Manufacturers of Heart Failure Drugs, Date of Entry into the Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Heart Failure Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Heart Failure Drugs Revenue, 2025
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Heart Failure Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 17. Global Heart Failure Drugs Sales by Region (MT), 2021–2026
 Table 18. Global Heart Failure Drugs Sales Market Share by Region (2021–2026)
 Table 19. Global Heart Failure Drugs Sales by Region (MT), 2027–2032
 Table 20. Global Heart Failure Drugs Sales Market Share by Region (2027–2032)
 Table 21. Global Heart Failure Drugs Revenue by Region (US$ Million), 2021–2026
 Table 22. Global Heart Failure Drugs Revenue Market Share by Region (2021–2026)
 Table 23. Global Heart Failure Drugs Revenue by Region (US$ Million), 2027–2032
 Table 24. Global Heart Failure Drugs Revenue Market Share by Region (2027–2032)
 Table 25. North America Heart Failure Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 26. North America Heart Failure Drugs Sales by Country (MT), 2021–2026
 Table 27. North America Heart Failure Drugs Sales by Country (MT), 2027–2032
 Table 28. North America Heart Failure Drugs Revenue by Country (US$ Million), 2021–2026
 Table 29. North America Heart Failure Drugs Revenue by Country (US$ Million), 2027–2032
 Table 30. Europe Heart Failure Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 31. Europe Heart Failure Drugs Sales by Country (MT), 2021–2026
 Table 32. Europe Heart Failure Drugs Sales by Country (MT), 2027–2032
 Table 33. Europe Heart Failure Drugs Revenue by Country (US$ Million), 2021–2026
 Table 34. Europe Heart Failure Drugs Revenue by Country (US$ Million), 2027–2032
 Table 35. Asia Pacific Heart Failure Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Asia Pacific Heart Failure Drugs Sales by Region (MT), 2021–2026
 Table 37. Asia Pacific Heart Failure Drugs Sales by Region (MT), 2027–2032
 Table 38. Asia Pacific Heart Failure Drugs Revenue by Region (US$ Million), 2021–2026
 Table 39. Asia Pacific Heart Failure Drugs Revenue by Region (US$ Million), 2027–2032
 Table 40. Latin America Heart Failure Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 41. Latin America Heart Failure Drugs Sales by Country (MT), 2021–2026
 Table 42. Latin America Heart Failure Drugs Sales by Country (MT), 2027–2032
 Table 43. Latin America Heart Failure Drugs Revenue by Country (US$ Million), 2021–2026
 Table 44. Latin America Heart Failure Drugs Revenue by Country (US$ Million), 2027–2032
 Table 45. Middle East and Africa Heart Failure Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 46. Middle East and Africa Heart Failure Drugs Sales by Country (MT), 2021–2026
 Table 47. Middle East and Africa Heart Failure Drugs Sales by Country (MT), 2027–2032
 Table 48. Middle East and Africa Heart Failure Drugs Revenue by Country (US$ Million), 2021–2026
 Table 49. Middle East and Africa Heart Failure Drugs Revenue by Country (US$ Million), 2027–2032
 Table 50. Global Heart Failure Drugs Sales (MT) by Type (2021–2026)
 Table 51. Global Heart Failure Drugs Sales (MT) by Type (2027–2032)
 Table 52. Global Heart Failure Drugs Sales Market Share by Type (2021–2026)
 Table 53. Global Heart Failure Drugs Sales Market Share by Type (2027–2032)
 Table 54. Global Heart Failure Drugs Revenue (US$ Million) by Type (2021–2026)
 Table 55. Global Heart Failure Drugs Revenue (US$ Million) by Type (2027–2032)
 Table 56. Global Heart Failure Drugs Revenue Market Share by Type (2021–2026)
 Table 57. Global Heart Failure Drugs Revenue Market Share by Type (2027–2032)
 Table 58. Global Heart Failure Drugs Price (USD/MT) by Type (2021–2026)
 Table 59. Global Heart Failure Drugs Price (USD/MT) by Type (2027–2032)
 Table 60. Global Heart Failure Drugs Sales (MT) by Application (2021–2026)
 Table 61. Global Heart Failure Drugs Sales (MT) by Application (2027–2032)
 Table 62. Global Heart Failure Drugs Sales Market Share by Application (2021–2026)
 Table 63. Global Heart Failure Drugs Sales Market Share by Application (2027–2032)
 Table 64. Global Heart Failure Drugs Revenue (US$ Million) by Application (2021–2026)
 Table 65. Global Heart Failure Drugs Revenue (US$ Million) by Application (2027–2032)
 Table 66. Global Heart Failure Drugs Revenue Market Share by Application (2021–2026)
 Table 67. Global Heart Failure Drugs Revenue Market Share by Application (2027–2032)
 Table 68. Global Heart Failure Drugs Price (USD/MT) by Application (2021–2026)
 Table 69. Global Heart Failure Drugs Price (USD/MT) by Application (2027–2032)
 Table 70. Novartis Company Information
 Table 71. Novartis Description and Business Overview
 Table 72. Novartis Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 73. Novartis Heart Failure Drugs Product
 Table 74. Novartis Recent Developments/Updates
 Table 75. Pfizer Company Information
 Table 76. Pfizer Description and Business Overview
 Table 77. Pfizer Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 78. Pfizer Heart Failure Drugs Product
 Table 79. Pfizer Recent Developments/Updates
 Table 80. AstraZeneca Company Information
 Table 81. AstraZeneca Description and Business Overview
 Table 82. AstraZeneca Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 83. AstraZeneca Heart Failure Drugs Product
 Table 84. AstraZeneca Recent Developments/Updates
 Table 85. Hikma Company Information
 Table 86. Hikma Description and Business Overview
 Table 87. Hikma Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 88. Hikma Heart Failure Drugs Product
 Table 89. Hikma Recent Developments/Updates
 Table 90. Teva Company Information
 Table 91. Teva Description and Business Overview
 Table 92. Teva Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 93. Teva Heart Failure Drugs Product
 Table 94. Teva Recent Developments/Updates
 Table 95. Cipla Company Information
 Table 96. Cipla Description and Business Overview
 Table 97. Cipla Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 98. Cipla Heart Failure Drugs Product
 Table 99. Cipla Recent Developments/Updates
 Table 100. Merck & Co. Company Information
 Table 101. Merck & Co. Description and Business Overview
 Table 102. Merck & Co. Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 103. Merck & Co. Heart Failure Drugs Product
 Table 104. Merck & Co. Recent Developments/Updates
 Table 105. Amgen Company Information
 Table 106. Amgen Description and Business Overview
 Table 107. Amgen Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 108. Amgen Heart Failure Drugs Product
 Table 109. Amgen Recent Developments/Updates
 Table 110. Roche Company Information
 Table 111. Roche Description and Business Overview
 Table 112. Roche Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 113. Roche Heart Failure Drugs Product
 Table 114. Roche Recent Developments/Updates
 Table 115. Sun Pharma Company Information
 Table 116. Sun Pharma Description and Business Overview
 Table 117. Sun Pharma Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 118. Sun Pharma Heart Failure Drugs Product
 Table 119. Sun Pharma Recent Developments/Updates
 Table 120. Mylan Company Information
 Table 121. Mylan Description and Business Overview
 Table 122. Mylan Heart Failure Drugs Sales (MT), Revenue (US$ Million), Price (USD/MT), and Gross Margin (2021–2026)
 Table 123. Mylan Heart Failure Drugs Product
 Table 124. Mylan Recent Developments/Updates
 Table 125. Key Raw Materials Lists
 Table 126. Raw Materials Key Suppliers Lists
 Table 127. Heart Failure Drugs Distributors List
 Table 128. Heart Failure Drugs Customers List
 Table 129. Heart Failure Drugs Market Trends
 Table 130. Heart Failure Drugs Market Drivers
 Table 131. Heart Failure Drugs Market Challenges
 Table 132. Heart Failure Drugs Market Restraints
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Heart Failure Drugs
 Figure 2. Global Heart Failure Drugs Market Value by Type (US$ Million), 2021–2032
 Figure 3. Global Heart Failure Drugs Market Share by Type: 2025 & 2032
 Figure 4. ACEI Product Picture
 Figure 5. Angiotensin II Receptor Blockers Product Picture
 Figure 6. ARNIs Product Picture
 Figure 7. Beta Blockers Product Picture
 Figure 8. Aldosterone Antagonists Product Picture
 Figure 9. Diuretics Product Picture
 Figure 10. Global Heart Failure Drugs Market Value by Application (US$ Million), 2021–2032
 Figure 11. Global Heart Failure Drugs Market Share by Application: 2025 & 2032
 Figure 12. Reduced Ejection Fraction
 Figure 13. Preserved Ejection Fraction
 Figure 14. Global Heart Failure Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 15. Global Heart Failure Drugs Market Size (US$ Million), 2021–2032
 Figure 16. Global Heart Failure Drugs Sales (MT), 2021–2032
 Figure 17. Global Heart Failure Drugs Average Price (USD/MT), 2021–2032
 Figure 18. Heart Failure Drugs Report Years Considered
 Figure 19. Heart Failure Drugs Sales Share by Manufacturers in 2025
 Figure 20. Global Heart Failure Drugs Revenue Share by Manufacturers in 2025
 Figure 21. Top 5 and Top 10 Global Heart Failure Drugs Players: Market Share by Revenue in Heart Failure Drugs in 2025
 Figure 22. Heart Failure Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
 Figure 23. Global Heart Failure Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Figure 24. North America Heart Failure Drugs Sales Market Share by Country (2021–2032)
 Figure 25. North America Heart Failure Drugs Revenue Market Share by Country (2021–2032)
 Figure 26. U.S. Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 27. Canada Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 28. Europe Heart Failure Drugs Sales Market Share by Country (2021–2032)
 Figure 29. Europe Heart Failure Drugs Revenue Market Share by Country (2021–2032)
 Figure 30. Germany Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 31. France Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 32. U.K. Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 33. Italy Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 34. Russia Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 35. Asia Pacific Heart Failure Drugs Sales Market Share by Region (2021–2032)
 Figure 36. Asia Pacific Heart Failure Drugs Revenue Market Share by Region (2021–2032)
 Figure 37. China Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 38. Japan Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 39. South Korea Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 40. India Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 41. Australia Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 42. Taiwan Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 43. Indonesia Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 44. Thailand Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 45. Malaysia Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 46. Philippines Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 47. Latin America Heart Failure Drugs Sales Market Share by Country (2021–2032)
 Figure 48. Latin America Heart Failure Drugs Revenue Market Share by Country (2021–2032)
 Figure 49. Mexico Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 50. Brazil Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 51. Argentina Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 52. Middle East and Africa Heart Failure Drugs Sales Market Share by Country (2021–2032)
 Figure 53. Middle East and Africa Heart Failure Drugs Revenue Market Share by Country (2021–2032)
 Figure 54. Turkey Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 55. Saudi Arabia Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 56. UAE Heart Failure Drugs Revenue Growth Rate (US$ Million), 2021–2032
 Figure 57. Global Sales Market Share of Heart Failure Drugs by Type (2021–2032)
 Figure 58. Global Revenue Market Share of Heart Failure Drugs by Type (2021–2032)
 Figure 59. Global Heart Failure Drugs Price (USD/MT) by Type (2021–2032)
 Figure 60. Global Sales Market Share of Heart Failure Drugs by Application (2021–2032)
 Figure 61. Global Revenue Market Share of Heart Failure Drugs by Application (2021–2032)
 Figure 62. Global Heart Failure Drugs Price (USD/MT) by Application (2021–2032)
 Figure 63. Heart Failure Drugs Value Chain
 Figure 64. Channels of Distribution (Direct Vs Distribution)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions